Company description

Exelixis, Inc. (EXEL) is a biopharmaceutical company that focuses on developing small molecule therapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Alameda, California. Exelixis has a diverse portfolio of clinical and preclinical development programs with a particular focus on targeted therapies that inhibit specific pathways involved in tumor growth and progression. The company's flagship product, Cabometyx, is currently approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma in the United States and several other countries. Exelixis also has a collaboration with Bristol-Myers Squibb for the development and commercialization of Cabometyx. In addition to its cancer programs, the company also has a research and development pipeline targeting other diseases such as polycystic kidney disease and non-alcoholic steatohepatitis. Exelixis has established itself as a leader in the biopharmaceutical industry with its innovative approaches to drug development and commitment to improving patients' lives.